In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Merck, Lundbeck terminate sleep drug license deal

Executive Summary

Merck & Co. Inc. is licensing US rights to H. Lundbeck AS's (psychiatric and neurological drugs) sleep disorder treatment gaboxadol. The companies will complete ongoing Phase III trials jointly, Merck paying most of the costs.
Deal Industry
  • Pharmaceuticals
Deal Status
  • Terminated
Deal Type
  • Alliance
    • Co-Promotion
    • R+D and Marketing-Licensing
    • Product or Technology Swap

Related Companies

Advertisement
UsernamePublicRestriction

Register